High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma

Kono,Hiroshi; Nakamura,Masafumi; Ohtsuka,Takao; Nagayoshi,Yosuke; Mori,Yasuhisa; Takahata,Shunichi; Aishima,Shinichi; Tanaka,Masao

doi:10.3892/or.2013.2443

High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma

Authors:
- Hiroshi Kono
- Masafumi Nakamura
- Takao Ohtsuka
- Yosuke Nagayoshi
- Yasuhisa Mori
- Shunichi Takahata
- Shinichi Aishima
- Masao Tanaka
View Affiliations

Affiliations: Department of Surgery and Oncology, Kyushu University, Fukuoka 812-8582, Japan, Department of Digestive Surgery, Kawasaki Medical School, Okayama 701-0192, Japan, Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
Published online on: May 9, 2013 https://doi.org/10.3892/or.2013.2443
Pages: 17-24
Copyright: © Kono et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis of gallbladder cancer (GBC) remains poor despite recent advances in diagnostics and therapeutic strategies. Although the role of microRNAs (miRs) in GBC have not been well documented, miR-155 is known to be associated with inflammation-associated carcinogenesis in various types of cancers. The aim of this study was to investigate the clinical significance of miR-155 expression and the biological functions of miR-155 in GBC. The expression levels of miR-155 in surgically resected GBCs and gallbladders with pancreaticobiliary maljunction (PBM) were assessed by quantitative reverse transcription-polymerase chain reaction. The relationship between the expression levels of miR-155 and clinicopathological features of GBCs was analyzed. Human GBC cell lines were transfected with miR-155 inhibitors or mimics, and the effects on proliferation and invasion were assessed. miR-155 was significantly overexpressed in GBCs when compared with that in gallbladders with PBM (p=0.007) and normal gallbladders (p=0.04). The high expression level of miR-155 in GBCs was significantly associated with the presence of lymph node metastasis (p=0.01) and a poor prognosis (p=0.02). In vitro assays showed that aberrant expression of miR-155 significantly enhanced GBC cell proliferation and invasion. In conclusion, high miR-155 expression correlates with the aggressive behavior of GBCs, and miR-155 may become a prognostic marker and therapeutic target for GBC.

View Figures

View References

1	Carriaga MT and Henson DE: Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 75:171–190. 1995. View Article : Google Scholar : PubMed/NCBI
2	Glauser PM, Strub D, Kaser SA, Mattiello D, Rieben F and Maurer CA: Incidence, management, and outcome of incidental gallbladder carcinoma: analysis of the database of the Swiss Association of Laparoscopic and Thoracoscopic Surgery. Surg Endosc. 24:2281–2286. 2010. View Article : Google Scholar
3	Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E and Salemis NS: Gallbladder cancer. Am J Surg. 196:252–264. 2008. View Article : Google Scholar
4	Sugiyama Y, Kobori H, Hakamada K, Seito D and Sasaki M: Altered bile composition in the gallbladder and common bile duct of patients with anomalous pancreaticobiliary ductal junction. World J Surg. 24:17–21. 2000. View Article : Google Scholar : PubMed/NCBI
5	Hanada K, Itoh M, Fujii K, et al: Pathology and cellular kinetics of gallbladder with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol. 91:1007–1011. 1996.PubMed/NCBI
6	Matsubara T, Sakurai Y, Zhi LZ, Miura H, Ochiai M and Funabiki T: K-ras and p53 gene mutations in noncancerous biliary lesions of patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg. 9:312–321. 2002. View Article : Google Scholar : PubMed/NCBI
7	Tsuchida A and Itoi T: Carcinogenesis and chemoprevention of biliary tract cancer in pancreaticobiliary maljunction. World J Gastrointest Oncol. 2:130–135. 2010. View Article : Google Scholar : PubMed/NCBI
8	Xiong L, Yang Z, Yang L, Liu J and Miao X: Expressive levels of MUC1 and MUC5AC and their clinicopathologic significances in the benign and malignant lesions of gallbladder. J Surg Oncol. 105:97–103. 2011. View Article : Google Scholar : PubMed/NCBI
9	Shimada K, Yanagisawa J and Nakayama F: Increased lysophosphatidylcholine and pancreatic enzyme content in bile of patients with anomalous pancreaticobiliary ductal junction. Hepatology. 13:438–444. 1991. View Article : Google Scholar
10	Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar
11	Griffiths-Jones S: miRBase: microRNA sequences and annotation. Curr Protoc Bioinformatics. Chapter 12(Unit 12): 91–10. 2010. View Article : Google Scholar
12	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar
13	Gironella M, Seux M, Xie MJ, et al: Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA. 104:16170–16175. 2007. View Article : Google Scholar : PubMed/NCBI
14	Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
15	Jiang S, Zhang HW, Lu MH, et al: MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70:3119–3127. 2010. View Article : Google Scholar : PubMed/NCBI
16	Eis PS, Tam W, Sun L, et al: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI
17	Tili E, Michaille JJ, Wernicke D, et al: Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci USA. 108:4908–4913. 2011. View Article : Google Scholar : PubMed/NCBI
18	Gregory PA, Bert AG, Paterson EL, et al: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008. View Article : Google Scholar : PubMed/NCBI
19	Zhang L, Mizumoto K, Sato N, et al: Quantitative determination of apoptotic death in cultured human pancreatic cancer cells by propidium iodide and digitonin. Cancer Lett. 142:129–137. 1999. View Article : Google Scholar : PubMed/NCBI
20	Shibuya H, Iinuma H, Shimada R, Horiuchi A and Watanabe T: Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 79:313–320. 2010. View Article : Google Scholar : PubMed/NCBI
21	Zhou SL and Wang LD: Circulating microRNAs: novel biomarkers for esophageal cancer. World J Gastroenterol. 16:2348–2354. 2010. View Article : Google Scholar : PubMed/NCBI
22	Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010. View Article : Google Scholar : PubMed/NCBI
23	Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
24	Kosaka N, Iguchi H and Ochiya T: Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010. View Article : Google Scholar : PubMed/NCBI
25	Fang C, Zhu DX, Dong HJ, et al: Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol. 91:553–559. 2011. View Article : Google Scholar : PubMed/NCBI
26	Lawrie CH, Gal S, Dunlop HM, et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
27	Shigehara K, Yokomuro S, Ishibashi O, et al: Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One. 6:e235842011. View Article : Google Scholar
28	Kasinski AL and Slack FJ: MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 11:849–864. 2011. View Article : Google Scholar : PubMed/NCBI
29	Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
30	Xie Q, Chen X, Lu F, et al: Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer. 118:2431–2442. 2012. View Article : Google Scholar : PubMed/NCBI